Merck may be getting some competition in time with the HPV Vaccine business, but the research here will focus on using plants, which they state will provide a vaccine at a cost less to the consumer. BD
Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program. The vaccine, to be produced in tobacco plants, targets the L2 protein, an integral part of the papillomavirus capsid. Preclinical research indicates that this development strategy may yield a vaccine that provides broader immune protection against a greater number of the approximate 200 HPV subtypes, as well as provide a more cost-effective alternative to the currently available options to patients. As such, the vaccine could have a significant impact on reducing the global incidence of HPV-linked cancers, including cervical cancer.